Abstract
HIV counseling with testing has been part of HIV prevention in the U.S. since the 1980s. Despite the long-standing history of HIV testing with prevention counseling, the CDC released HIV testing recommendations for health care settings contesting benefits of prevention counseling with testing in reducing sexual risk behaviors among HIV-negatives in 2006. Efficacy of brief HIV risk-reduction counseling (RRC) in decreasing sexual risk among subgroups of substance use treatment clients was examined using multi-site RCT data. Interaction tests between RRC and subgroups were performed; multivariable regression evaluated the relationship between RRC (with rapid testing) and sex risk. Subgroups were defined by demographics, risk type and level, attitudes/perceptions, and behavioral history. There was an effect (p < .0028) of counseling on number of sex partners among some subgroups. Certain subgroups may benefit from HIV RRC; this should be examined in studies with larger sample sizes, designed to assess the specific subgroup(s).
Resumen
Consejería con pruebas de VIH han sido parte de la prevención de VIH en los EE.UU. desde los 1980s. A pesar de una larga historia de pruebas de VIH con consejería sobre prevención, en el 2006 el CDC publicó una serie de recomendaciones para los centros de atención de salud disputando los beneficios de la consejería sobre prevención con pruebas para la reducción de comportamientos sexuales de riesgo entre personas VIH-negativas. Se examinó la eficacia de la consejería breve sobre reducción de riesgo (RRC, por sus siglas en inglés) de VIH en la disminución del riesgo sexual entre subgrupos de pacientes en tratamiento de uso de sustancias utilizando datos de un ensayo clínico multi-centro. Se realizaron pruebas de interacción entre RCC y los subgrupos; una regresión multivariada donde se evaluó la relación entre RCC (con pruebas rápida) y riesgo sexual. Los subgrupos fueron definidos por las características sociodemográficas, tipo y nivel de riesgo, actitudes/percepciones e historial de comportamiento. Se encontró que la consejería tuvo efecto (p < .0028) en el número de parejas sexuales entre algunos subgrupos. Ciertos subgrupos podrían beneficiarse de RRC de VIH; esto debe ser examinado en estudios con muestras más grandes, diseñados para evaluar subgrupos específicos.
Similar content being viewed by others
References
Branson BM, Handsfield HH, Lampe MA, et al. Revised recommendations for HIV testing of adults, adolescents, and pregnant women in health-care settings. MMWR Recomm Rep. 2006;55(RR-14):1–17 quiz CE1-4.
Vermund SH, Hodder SL, Justman JE, et al. Addressing research priorities for prevention of HIV infection in the United States. Clin Infect Dis. 2010;15(50 Suppl 3):S149–55.
Boone MR, Cook SH, Wilson P. Substance use and sexual risk behavior in HIV-positive men who have sex with men: an episode-level analysis. AIDS Behav. 2013;17(5):1883–7.
Beyrer C, Wirtz AL, Baral S, Peryskina A, Sifakis F. Epidemiologic links between drug use and HIV epidemics: an international perspective. J Acquir Immune Defic Syndr. 2010;55(Suppl 1):S10–6.
Booth RE, Campbell BK, Mikulich-Gilbertson SK, et al. Reducing HIV-related risk behaviors among injection drug users in residential detoxification. AIDS Behav. 2011;15(1):30–44.
Ross MW, Hwang LY, Zack C, Bull L, Williams ML. Sexual risk behaviours and STIs in drug abuse treatment populations whose drug of choice is crack cocaine. Int J STD AIDS. 2002;13(11):769–74.
Masur H, Michelis MA, Greene JB, et al. An outbreak of community-acquired Pneumocystis carinii pneumonia: initial manifestation of cellular immune dysfunction. N Engl J Med. 1981;305(24):1431–8.
Mathers BM, Degenhardt L, Phillips B, et al. Global epidemiology of injecting drug use and HIV among people who inject drugs: a systematic review. Lancet. 2008;372(9651):1733–45.
De Cock KM, Jaffe HW, Curran JW. Reflections on 30 years of AIDS. Emerg Infect Dis. 2011;17(6):1044–8.
Gostin L. The epidemics of injection drug use and blood-borne disease: a public health perspective. Georgetown University Law Center. Val U L Rev. 1997;31:669–700.
Mathers B, Cook C, Degenhardt L. Improving the data to strengthen the global response to HIV among people who inject drugs. Int J Drug Policy. 2010;21(2):100–2.
Centers for Disease Control and Prevention (CDC). Risk, Prevention, and Testing Behaviors Related to HIV and Hepatitis Infections—National HIV Behavioral Surveillance System: Injecting Drug Users, May 2005–February 2006. HIV Special Surveillance Report 7. 2011. http://www.cdc.gov/hiv/pdf/statistics_hiv_surveillance_special_report_no_7.pdf. Accessed July 14, 2011.
Broz D, Wejnert C, Pham HT, et al. HIV infection and risk, prevention, and testing behaviors among injecting drug users—National HIV Behavioral Surveillance System, 20 U.S. cities, 2009. MMWR Surveill Summ. 2014;63(6):1–51.
Volkow ND, Montaner J. Enhanced HIV testing, treatment, and support for HIV-infected substance users. JAMA. 2010;303(14):1423–4.
Volkow ND, Wang GJ, Fowler JS, Telang F, Jayne M, Wong C. Stimulant-induced enhanced sexual desire as a potential contributing factor in HIV transmission. Am J Psychiatry. 2007;164(1):157–60.
Centers for Disease Control and Prevention (CDC). HIV-associated behaviors among injecting-drug users–23 Cities, United States, May 2005-February 2006. MMWR Morb Mortal Wkly Rep. 2009;58(13):329–32.
Molitor F, Truax SR, Ruiz JD, Sun RK. Association of methamphetamine use during sex with risky sexual behaviors and HIV infection among non-injection drug users. West J Med. 1998;168(2):93–7.
Strathdee SA, Sherman SG. The role of sexual transmission of HIV infection among injection and non-injection drug users. J Urban Health. 2003;80(4 Suppl 3):iii7–14.
Marshall BD, Wood E. Toward a comprehensive approach to HIV prevention for people who use drugs. J Acquir Immune Defic Syndr. 2010;55(Suppl 1):S23–6.
Centers for Disease Control and Prevention (CDC). HIV infection and HIV-associated behaviors among injecting drug users—20 cities, United States, 2009. MMWR Morb Mortal Wkly Rep. 2012;61(8):133–8.
Tross S, Hanner J, Hu MC, Pavlicova M, Campbell A, Nunes EV. Substance use and high risk sexual behaviors among women in psychosocial outpatient and methadone maintenance treatment programs. Am J Drug Alcohol Abuse. 2009;35(5):368–74.
Calsyn DA, Cousins SJ, Hatch-Maillette MA, et al. Sex under the influence of drugs or alcohol: common for men in substance abuse treatment and associated with high-risk sexual behavior. Am J Addict. 2010;19(2):119–27.
McHugh RK, Weitzman M, Safren SA, Murray HW, Pollack MH, Otto MW. Sexual HIV risk behaviors in a treatment-refractory opioid-dependent sample. J Psychoact Drugs. 2012;44(3):237–42.
Metsch LR, Feaster DJ, Gooden L, et al. Implementing rapid HIV testing with or without risk-reduction counseling in drug treatment centers: results of a randomized trial. Am J Public Health. 2012;102(6):1160–7.
Schackman BR, Metsch LR, Colfax GN, et al. The cost-effectiveness of rapid HIV testing in substance abuse treatment: results of a randomized trial. Drug Alcohol Depend. 2013;128(1–2):90–7.
The White House Office of National AIDS Policy. National HIV/AIDS Strategy for the United States: Updated to 2020. 2015. https://www.aids.gov/federal-resources/national-hiv-aids-strategy/nhas-update.pdf. Accessed Aug 11, 2015.
Department of Health and Human Services (DHHS). HIV testing objectives. 2011. http://www.healthypeople.gov/2020/topicsobjectives2020/objectiveslist.aspx?topicId=22. Accessed Aug 8, 2011.
Kellam SG, Brown CH, Poduska JM, et al. Effects of a universal classroom behavior management program in first and second grades on young adult behavioral, psychiatric, and social outcomes. Drug Alcohol Depend. 2008;1(95 Suppl 1):S5–28.
Gibbons RD, Hur K, Brown CH, Davis JM, Mann JJ. Benefits from antidepressants: synthesis of 6-week patient-level outcomes from double-blind placebo-controlled randomized trials of fluoxetine and venlafaxine. Arch Gen Psychiatry. 2012;69(6):572–9.
Materson BJ. Variability in response to antihypertensive drugs. Am J Med. 2007;120(4 Suppl 1):S10–20.
Stroup TS. Heterogeneity of treatment effects in schizophrenia. Am J Med. 2007;120(4 Suppl 1):S26–31.
Kaplan SH, Billimek J, Sorkin DH, Ngo-Metzger Q, Greenfield S. Who can respond to treatment? Identifying patient characteristics related to heterogeneity of treatment effects. Med Care. 2010;48(6 Suppl):S9–16.
Su X, Meneses K, McNees P, Johnson WO. Interaction trees: exploring the differential effects of an intervention programme for breast cancer survivors. J R Stat Soc C-App. 2011;60:457–74.
Metcalf CA, Douglas JM Jr, Malotte CK, et al. Relative efficacy of prevention counseling with rapid and standard HIV testing: a randomized, controlled trial (RESPECT-2). Sex Transm Dis. 2005;32(2):130–8.
Koblin B, Chesney M, Coates T, EXPLORE Study Team. Effects of a behavioural intervention to reduce acquisition of HIV infection among men who have sex with men: the EXPLORE randomised controlled study. Lancet. 2004;364(9428):41–50.
Koblin BA, Husnik MJ, Colfax G, et al. Risk factors for HIV infection among men who have sex with men. AIDS. 2006;20(5):731–9.
Clark LR, Brasseux C, Richmond D, Getson P, D’Angelo LJ. Effect of HIV counseling and testing on sexually transmitted diseases and condom use in an urban adolescent population. Arch Pediatr Adolesc Med. 1998;152(3):269–73.
Bolu OO, Lindsey C, Kamb ML, et al. Is HIV/sexually transmitted disease prevention counseling effective among vulnerable populations?: a subset analysis of data collected for a randomized, controlled trial evaluating counseling efficacy (Project RESPECT). Sex Transm Dis. 2004;31(8):469–74.
Kamb ML, Fishbein M, Douglas JM Jr, et al. Efficacy of risk-reduction counseling to prevent human immunodeficiency virus and sexually transmitted diseases: a randomized controlled trial. Project RESPECT Study Group. JAMA. 1998;280(13):1161–7.
Song YS, Calsyn DA, Doyle SR, Dierst-Davies R, Chen T, Sorensen JL. Predictors of condom use among men enrolled in drug treatment programs. AIDS Educ Prev. 2009;21(5):460–73.
Centers for Disease Control and Prevention (CDC). Characteristics associated with HIV infection among heterosexuals in urban areas with high AIDS prevalence—24 cities, United States, 2006-2007. MMWR Morb Mortal Wkly Rep. 2011;60(31):1045–9.
Brown-Peterside P, Redding CA, Ren L, Koblin BA. Acceptability of a stage-matched expert system intervention to increase condom use among women at high risk of HIV infection in New York City. AIDS Educ Prev. 2000;12(2):171–81.
Catania JA, Kegeles SM, Coates TJ. Towards an understanding of risk behavior: an AIDS risk reduction model (ARRM). Health Educ Q. Spring. 1990;17(1):53–72.
Becker MH. AIDS and behavior change. Public Health Rev. 1998;16:1–11.
Brafford LJ, Beck KH. Development and validation of a condom self-efficacy scale for college students. J Am Coll Health. 1991;39(5):219–25.
Brien TM, Thombs DL, Mahoney CA, Wallnau L. Dimensions of self-efficacy among three distinct groups of condom users. J Am Coll Health. 1994;42(4):167–74.
DeHart DD, Birkimer JC. Trying to practice safer sex: development of the sexual risks scale. J Sex Res. 1997;34(1):11–25.
Yudko E, Lozhkina O, Fouts A. A comprehensive review of the psychometric properties of the drug abuse screening test. J Subst Abuse Treat. 2007;32(2):189–98.
Rietmeijer CA. Risk reduction counselling for prevention of sexually transmitted infections: how it works and how to make it work. Sex Transm Infect. 2007;83(1):2–9.
Dilley JW, Woods WJ, Sabatino J, et al. Changing sexual behavior among gay male repeat testers for HIV: a randomized, controlled trial of a single-session intervention. J Acquir Immune Defic Syndr. 2002;30(2):177–86.
Wolfe D, Cohen J. Human rights and HIV prevention, treatment, and care for people who inject drugs: key principles and research needs. J Acquir Immune Defic Syndr. 2010;55(Suppl 1):S56–62.
Wohl DA, Rosen D, Kaplan AH. HIV and incarceration: dual epidemics. AIDS Read. 2006;16(5):247–.
Corneil TA, Kuyper LM, Shoveller J, et al. Unstable housing, associated risk behaviour, and increased risk for HIV infection among injection drug users. Health Place. 2006;12(1):79–85.
Surratt HL, Inciardi JA. HIV risk, seropositivity and predictors of infection among homeless and non-homeless women sex workers in Miami, Florida. USA. AIDS Care. 2004;16(5):594–604.
Aidala AA, Lee G, Garbers S, Chiasson MA. Sexual behaviors and sexual risk in a prospective cohort of HIV-positive men and women in New York City, 1994-2002: implications for prevention. AIDS Educ Prev. 2006;18(1):12–32.
Dickson-Gomez J, Hilario H, Convey M, Corbett AM, Weeks M, Martinez M. The relationship between housing status and HIV risk among active drug users: a qualitative analysis. Subst Use Misuse. 2009;44(2):139–62.
Centers for Disease Control and Prevention (CDC). The role of STD detection and treatment in HIV prevention—CDC fact sheet. 2010. http://www.cdc.gov/std/hiv/stdfact-std-hiv.htm. Accessed July, 2011.
Ng BE, Butler LM, Horvath T, Rutherford GW. Population-based biomedical sexually transmitted infection control interventions for reducing HIV infection. Cochrane Database Syst Rev. 2011;16(3):1220.
Stein JA, Nyamathi A, Ullman JB, Bentler PM. Impact of marriage on HIV/AIDS risk behaviors among impoverished, at-risk couples: a multilevel latent variable approach. AIDS Behav. 2007;11(1):87–98.
Finer LB, Darroch JE, Singh S. Sexual partnership patterns as a behavioral risk factor for sexually transmitted diseases. Fam Plann Perspect. 1999;31(5):228–36.
Rush AJ, Trivedi MH, Ibrahim HM, et al. The 16-item quick inventory of depressive symptomatology (QIDS), clinician rating (QIDS-C), and self-report (QIDS-SR): a psychometric evaluation in patients with chronic major depression. Biol Psychiatry. 2003;54(5):573–83.
Mizuno Y, Purcell DW, Mackenzie S, et al. Acceptability of A-CASI by HIV-positive IDUs in a multisite, randomized, controlled trial of behavioral intervention (INSPIRE). J Acquir Immune Defic Syndr. 2007;1(46 Suppl 2):S48–54.
Zimmerman RS, Langer LM. Improving estimates of prevalence rates of sensitive behaviors: the randomized lists technique and consideration of self-reported honesty. J Sex Res. 1995;32:107–17.
Metsch LR, Feaster DJ, Gooden L, et al. Effect of risk-reduction counseling with rapid HIV testing on risk of acquiring sexually transmitted infections: the aware randomized clinical trial. JAMA. 2013;310(16):1701–10.
Peterman TA, Lin LS, Newman DR, et al. Does measured behavior reflect STD risk? An analysis of data from a randomized controlled behavioral intervention study. Project RESPECT study Group. Sex Transm Dis. 2000;27(8):446–51.
Weinhardt LS, Carey MP, Johnson BT, Bickham NL. Effects of HIV counseling and testing on sexual risk behavior: a meta-analytic review of published research, 1985-1997. Am J Public Health. 1999;89(9):1397–405.
Centers for Disease Control and Prevention (CDC). Recommendations for HIV testing services and outpatients in acute-care hospital settings; and Technical guidance on HIV counseling. MMWR Recomm Rep. 1993;42(2):5–9.
Assmann SF, Pocock SJ, Enos LE, Kasten LE. Subgroup analysis and other (mis)uses of baseline data in clinical trials. Lancet. 2000;355(9209):1064–9.
Brookes ST, Whitley E, Peters TJ, Mulheran PA, Egger M, Davey SG. Subgroup analyses in randomised controlled trials: quantifying the risks of false-positives and false-negatives. Health Technol Assess. 2001;5(33):1–56.
Brookes ST, Whitely E, Egger M, Smith GD, Mulheran PA, Peters TJ. Subgroup analyses in randomized trials: risks of subgroup-specific analyses; power and sample size for the interaction test. J Clin Epidemiol. 2004;57(3):229–36.
Cui L, Hung HM, Wang SJ, Tsong Y. Issues related to subgroup analysis in clinical trials. J Biopharm Stat. 2002;12(3):347–58.
Lagakos SW. The challenge of subgroup analyses–reporting without distorting. N Engl J Med. 2006;354(16):1667–9.
Peto R, Collins R, Gray R. Large-scale randomized evidence: large, simple trials and overviews of trials. J Clin Epidemiol. 1995;48(1):23–40.
Pocock SJ, Assmann SE, Enos LE, Kasten LE. Subgroup analysis, covariate adjustment and baseline comparisons in clinical trial reporting: current practice and problems. Stat Med. 2002;21(19):2917–30.
Rothwell PM. Treating individuals 2. Subgroup analysis in randomised controlled trials: importance, indications, and interpretation. Lancet. 2005;365(9454):176–86.
Yusuf S, Wittes J, Probstfield J, Tyroler HA. Analysis and interpretation of treatment effects in subgroups of patients in randomized clinical trials. JAMA. 1991;266(1):93–8.
Wang R, Lagakos SW, Ware JH, Hunter DJ, Drazen JM. Statistics in medicine–reporting of subgroup analyses in clinical trials. N Engl J Med. 2007;357(21):2189–94.
Chen X, Ishwaran H. Random forests for genomic data analysis. Genomics. 2012;99(6):323–9.
Foster JC, Taylor JM, Ruberg SJ. Subgroup identification from randomized clinical trial data. Stat Med. 2011;30(24):2867–80.
Acknowledgments
Funding for this study was provided by the National Drug Abuse Treatment Clinical Trials Network under the following cooperative agreements, awards, and contracts: U10DA013720, U10DA13720-09S, U10DA020036, U10DA15815, U10DA13034, U10DA013038, U10DA013732, U10DA13036, U10DA13727, U10DA015833, HHSN271200522081C, and HHSN271200522071C. Lisa R. Metsch, Ph.D. and Grant N. Colfax, M.D. were the Lead Investigators of the parent trial. Lauren Gooden, Lisa R. Metsch, Margaret R. Pereyra, C. Kevin Malotte, Louise F. Haynes, Antoine Douaihy, Jacky Chally and Daniel J. Feaster reported that their respective institutions received grant funds from the study sponsor in support of this study.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interest
LG, LRM, MRP, CKM, LFH, AD, JC and DJF reported that their respective institutions received grant funds from the study sponsor in support of this study. LG, LRM, AD, and JC reported that their respective institutions received support for travel related to this study. LG and JC reported that they and their respective institutions received funding from other grants from the study sponsor. No other disclosures were reported.
Ethical approval
All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. The Western Institutional Review Board (WIRB) reviewed and approved all procedures related to the parent trial.
Informed Consent
Informed consent was obtained from all individual participants included in the study.
Rights and permissions
About this article
Cite this article
Gooden, L., Metsch, L.R., Pereyra, M.R. et al. Examining the Efficacy of HIV Risk-Reduction Counseling on the Sexual Risk Behaviors of a National Sample of Drug Abuse Treatment Clients: Analysis of Subgroups. AIDS Behav 20, 1893–1906 (2016). https://doi.org/10.1007/s10461-016-1300-6
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10461-016-1300-6